Condition: Cocaine Use Disorder · HIV · Sponsor: University of Maryland, Baltimore
The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's
This description comes directly from the study's public registry record.
Onyinyechi Ogbumbadiugha-Weekes · 443-635-4943 · oogbumbadiugha@ihv.umaryland.edu
Sarah Kattakuzhy · 443-691-4638 · skattakuzhy@ihv.umaryland.edu
Always discuss trial participation with your own doctor first.
| Institute of Human Virology at the University of Maryland School of Medicine | Washington D.C., District of Columbia, United States | Recruiting |
| Institute of Human Virology at the University of Maryland School of Medicine | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06691243